Immunotherapy Resistance in Pancreatic Cancer

Video

This video examines the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting and trials attempting to confront this problem.

In this video, Gregory L. Beatty, MD, PhD, of the University of Pennsylvania, discusses the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting, and how trials are being designed to confront this problem.

Beatty gave a presentation on this subject at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Related Content
Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

Improvements Over Chemo Yield Sotorasib Combo Approval in KRAS G12C+ CRC

Russ Conroy
Published: February 11th 2025 | Updated: February 11th 2025
Article

Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer

Russ Conroy
February 1st 2025
Article

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC

Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC

Tim Cortese
January 30th 2025
Article

Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

Russ Conroy
January 29th 2025
Article

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.